Please assess the completion status of the following clinical trial:

Trial Title: Nobori Dual Antiplatelet Therapy as Appropriate Duration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects \> 20 years old~* Undergoing percutaneous intervention with Nobori deployment~* No contraindication to prolonged DAPT~Exclusion Criteria:~* Subjects absolutely necessitating continuous DAPT~* Planned surgery necessitating discontinuation of antiplatelet therapy after enrollment.~* Active pathological bleeding~* Status of cardiogenic shock at enrollment~* Pregnant women~* Life expectancy of \< 1.5 years~* Subjects unable to give informed consent~* Episode of stroke \< 6 months~* Subjects with allergies or hypersensitivity to material of coating, Biolimus A9, and antiplatelet drugs.~* Subjects treated with other kind of DES or BMS during the index procedure~* Previous intervention with DES \< 6 months.~* Study participation impractical per investigator judgment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Short-term DAPT (6 months) group (Type: EXPERIMENTAL): 6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
- Long-term DAPT (18 months) group (Type: EXPERIMENTAL): 18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent

Based on this trial design, predict the completion outcome and termination type (if applicable).